TCG Crossover Management, LLC Q2 2022 Filing
Filed August 15, 2022
Portfolio Value
$235.4B
Holdings
22
Report Date
Q2 2022
Filing Type
13F-HR
All Holdings (22 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 1 | COGTCogent Biosciences, Inc. | 3,481,042 | $31.4B | 13.34% | |
| 2 | OPHTEURIveric Bio, Inc. | 2,914,250 | $28.0B | 11.91% | |
| 3 | GONGeron Corporation | 15,096,342 | $23.4B | 9.94% | |
| 4 | KURAKura Oncology, Inc. | 1,167,642 | $21.4B | 9.09% | |
| 5 | CBAYUSDCymaBay Therapeutics, Inc. | 5,905,400 | $17.4B | 7.40% | |
| 6 | ACRSAclaris Therapeuitics, Inc. | 1,144,939 | $16.0B | 6.79% | |
| 7 | VRDNViridian Therapeutics Inc | 1,314,000 | $15.2B | 6.46% | |
| 8 | 290AChinook Therapeutics, Inc. | 796,460 | $13.9B | 5.92% | |
| 9 | AVTEAerovate Therapeutics, Inc. | 889,572 | $13.9B | 5.91% | |
| 10 | TRDAEntrada Therapeutics, Inc. | 663,694 | $8.1B | 3.43% | |
| 11 | MRUSMerus N.V. | 300,000 | $6.8B | 2.89% | |
| 12 | TYRATyra Biosciences, Inc. | 896,418 | $6.4B | 2.72% | |
| 13 | —Akouos, Inc. | 1,350,006 | $6.3B | 2.69% | |
| 14 | TNGXTango Therapeutics, Inc. | 1,172,250 | $5.3B | 2.26% | |
| 15 | MLTXMoonLake Immunotherapeutics | 1,000,000 | $5.3B | 2.23% | |
| 16 | NVLSEURAlpine Immune Sciences, Inc. | 578,260 | $4.9B | 2.09% | |
| 17 | ETNBGBP89bio, Inc. | 1,133,196 | $3.6B | 1.55% | |
| 18 | ZLABZai Lab LTD-ADR | 95,000 | $3.3B | 1.40% | |
| 19 | —Magenta Therapeutics, Inc. | 2,124,122 | $2.5B | 1.08% | |
| 20 | ANABAnaptysBio, Inc. | 58,515 | $1.2B | 0.50% | |
| 21 | —Elevation Oncology, Inc. | 555,000 | $777.0M | 0.33% | |
| 22 | —Pardes Biosciences, Inc. | 59,039 | $181.0M | 0.08% |